Jacobus Pharmaceutical Company is voluntarily recalling 3 lots of Ruzurgi® (amifampridine) 10mg tablets due to yeast, mold, and aerobic bacterial contamination based laboratory test results.
The 3 recalled lots of Ruzurgi 10mg tablets; NDC 49938-110-01, were distributed worldwide to specialty pharmacies and physicians, and include the following:
- Control Number 18038; Expiration Date 3/2023; Distributed between 5/25/2021 – 8/26/2021 (Canada only);
- Control Number 18039; Expiration Date 3/2023; Distributed between 6/1/2021 – 8/10/2021;
- Control Number 18079; Expiration Date 5/2023; Distributed between 8/10/2021 – 8/30/2021.
Ruzurgi is a potassium channel blocker indicated for the treatment of Lambert Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age. According to the Company, use of the recalled product in patients with LEMS increases the risk of serious and life-threatening infections.
Continue Reading
Adverse events associated with the recall should be reported to the Food and Drug Administration’s MedWatch program.
For more information contact Jacobus Pharmaceutical Company by calling (609) 799-8221, Extension 2120.
Reference
Jacobus Pharmaceutical Company Inc. issues voluntary worldwide recall of Ruzurgi® (amifampridine) 10 mg tablets due to yeast, mold, and bacterial contamination. News release. US Food and Drug Administration. Accessed September 14, 2021. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/jacobus-pharmaceutical-company-inc-issues-voluntary-worldwide-recall-ruzurgir-amifampridine-10-mg.
This article originally appeared on MPR
